Manasa Narasimman
Overview
Explore the profile of Manasa Narasimman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gurley T, Hernaez R, Cerda V, Thomas T, Narasimman M, Mittal S, et al.
EClinicalMedicine
. 2025 Mar;
81:103113.
PMID: 40040860
Background: Patients with cirrhosis are at high risk for hepatocellular carcinoma (HCC), but few undergo guideline-recommended semi-annual screening. Randomized clinical trials (RCTs) demonstrate that mailed outreach can increase screening versus...
2.
Singal A, Daher D, Narasimman M, Mhi S, Yekkaluri S, Liu Y, et al.
J Natl Cancer Inst
. 2024 Sep;
117(2):262-269.
PMID: 39288308
Background: The value of hepatocellular carcinoma screening is defined by the balance of benefits from early tumor detection vs harms because of false-positive results. We evaluated the value of a...
3.
Singal A, Narasimman M, Daher D, Yekkaluri S, Liu Y, Lee M, et al.
Gut
. 2024 Jun;
73(12):2037-2044.
PMID: 38839269
Background: Hepatocellular carcinoma (HCC) is plagued by failures across the cancer care continuum, leading to frequent late-stage diagnoses and high mortality. We evaluated the effectiveness of mailed outreach invitations plus...
4.
Narasimman M, Hernaez R, Cerda V, Lee M, Yekkaluri S, Khan A, et al.
Clin Gastroenterol Hepatol
. 2023 Aug;
22(4):760-767.e1.
PMID: 37544418
Background: The overall value of hepatocellular carcinoma screening is defined by the balance of benefits and harms. Studies have only reported physical harms with none describing financial harms. Methods: We...
5.
Narasimman M, Hernaez R, Cerda V, Lee M, Sood A, Yekkaluri S, et al.
Hepatology
. 2023 Jul;
79(1):107-117.
PMID: 37401857
Background And Aims: The value of HCC surveillance is determined by the balance between benefits and harms; however, no studies have enumerated psychological harms. Approach And Results: We fielded surveys...
6.
Narasimman M, Pruitt S, Murphy C, Singal A, Tavakkoli A
Cancer Epidemiol Biomarkers Prev
. 2023 Jun;
32(9):1169-1173.
PMID: 37352435
Background: The incidence of noncardia gastric cancer is increasing in adults ages less than 50 years old. Early-onset gastric cancer (EOGC) is characterized by ethnic disparities occurring more in Hispanic...
7.
Kassab I, Singal A, Ali A, Narasimman M, Arvind A, Ahmed M, et al.
Hepatol Commun
. 2023 Mar;
7(4).
PMID: 36972387
Background Aims: Locoregional therapies, including transarterial chemoembolization (TACE), are recommended for the treatment of HCC; however, clinical trials evaluating their effectiveness have been complicated by a lack of validated surrogate...
8.
Bergquist A, Weismuller T, Levy C, Rupp C, Joshi D, Nayagam J, et al.
Liver Int
. 2022 May;
43(1):127-138.
PMID: 35535655
Background & Aims: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies...
9.
Singal A, Zhang E, Narasimman M, Rich N, Waljee A, Hoshida Y, et al.
J Hepatol
. 2022 Feb;
77(1):128-139.
PMID: 35139400
Background & Aims: There is controversy regarding the overall value of hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis given the lack of data from randomized-controlled trials. To address this...
10.
Narasimman M, Mantero A, Ronquillo N, Chyou D, Goldberg D
Liver Transpl
. 2021 Oct;
28(4):717-721.
PMID: 34651414
No abstract available.